

20th Global Conference on Diabetes, Endocrinology and Primary Healthcare April 27-28, 2022 | Webinar

Volume: 08

Real world treatment outcomes with the use of SGLT2i: an experience from 6 tertiary Urban endocrine centres in India: special concentration on glycemic, metabolic and renal parameters

Santosh Ramakrishnan

Magna Centres for Obesity, Diabetes and Endocrinology, India

Background: SGLT2i have now firmly established as one of the prime choices in the management of Type 2 Diabetes. Apart from good glycemic control, weight loss and little or no [hypoglycemia](#), they have shown to have positive benefits on blood pressure, the lipid profile and heart function dynamics. Remarkable data suggest that these group of drugs have protective effects as far as atherosclerotic cardiovascular outcomes, heart failure risk and renal protection are concerned. This makes these drugs as front runners as first line therapy in many patients.

Aim: We plan to present the real-world outcome of patients prescribed with SGLT2i.

Methods. Retrospective data will be analyzed from the databases of six tertiary endocrine centers. Patients who were first prescribed on SGLT2i ([empagliflozin](#), [dapagliflozin](#), [canagliflozin](#) or [remogliflozin](#)) between January 2015 and January 2022 will be identified. Only the data of the patients who have successfully completed six months of follow up on the same drug will be analyzed. The baseline data will be collated and compared with data of the patients after 3 months and 6 months.

Results: The baseline data analysis will include baseline BMI at which these drugs are preferred, age of onset of the said therapy, baseline HbA1c and baseline renal parameters. Whether the SGLT2i were preferred as first line, second line, third line or further will be analyzed. The follow up data analysis will include study of change in fasting and post meal glucose values, change in Hba1c, weight, systolic and diastolic BP, [serum lipid parameters](#) (where available), urine microalbumin and serum creatinine.

Conclusion. This study hopes to throw insights onto the real-world glycemic and metabolic effects of SGLTi use in Indian urban centres.

Biography

Santosh Ramakrishnan , He is a Consultant Endocrinologist, Magna Centres for Obesity, Diabetes and Endocrinology, Filmnagar, Hyderabad, India.

dr.rasntosh@gmail.com